Nutra Pharma Corp., a biotechnology company that is developing drugs for HIV and Multiple Sclerosis, has announced that Designer Diagnostics will be participating in a medical workshop organized to educate physicians in India about their Test Kits. Designer Diagnostics is a wholly owned subsidiary of Nutra Pharma.
The workshop will take place on March 24, 2006, at the Mahatma Gandhi Institute. Physicians will receive CME credits for attending. The workshop will include guest lecturers from the World Health Organization (WHO), JALMA Institute for Leprosy and other Mycobacterial Diseases, Grant Medical College, JJ Hospital Mumbai, the Mahatma Gandhi Institute, and Designer Diagnostics Inc. Invited to the CME are forty top Indian Microbiologists as well as leading diagnostic test distributors.
"Included in the agenda will be an afternoon of demonstrations of Designer Diagnostics' paraffin slide culture to the participants," said Dr. Rahul Narang, Director of The Mahatma Gandhi Institute of Medicine's Department of Microbiology. "We shall demonstrate growth of non-tuberculous mycobacteria, biochemical reactions and drug sensitivity testing using paraffin slide culture."
"The Designer Diagnostics Test Kits will be a great asset in the efforts to control both Tuberculosis mycobacterium and non-tubercular mycobacteria such as M.avium, which are major causes of death in HIV/AIDS patients," said Neil Roth, President of Designer Diagnostics Inc. "The rapid methods of determining the existence and type of mycobacterium that the Test Kits bring to this important struggle can help dramatically reduce the suffering and deaths these diseases are causing today. This conference will be vital in sharing this information within the active Tuberculosis and microbiology communities."
Attending the convention will be Neil Roth and Dr. Robert Ollar, representing Designer Diagnostics Inc., and Steven Wilson, representing HealthForce LLC, the consulting firm hired to sell and market the Test Kits.
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The full-day Designer Diagnostics' workshop in India should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.